Warfarin
{"Image DocumentName": "Warfarin", "Image ImageDescription": "Warfarinin PT\u2019e etkisi doza ba\u011fl\u0131 olarak genellikle ilk iki-\u00fc\u00e7 g\u00fcnde, antitrombotik etkisi ise bunu takiben birka\u00e7 g\u00fcn i\u00e7inde ortaya \u00e7\u0131kar. Tedavi ba\u015flang\u0131c\u0131nda y\u00fckleme dozu (>20mg) \u00f6nerilmemektedir. Baz\u0131 \u00e7al\u0131\u015fmalarda, y\u00fcksek doz ile ba\u015flanmas\u0131n\u0131n etkin INR\u2019ye daha k\u0131sa s\u00fcrede ula\u015f\u0131lmas\u0131n\u0131 sa\u011flayaca\u011f\u0131 bildirilmesine ra\u011fmen, \u00e7o\u011fu hastada ilk bir-iki g\u00fcn 5-10mg dozunda ba\u015flan\u0131p, daha sonra INR yan\u0131t\u0131na g\u00f6re dozun ayarlanmas\u0131 \u00f6nerilmektedir. Ya\u015fl\u0131 hastalarda (>60 ya\u015f) ba\u015flang\u0131\u00e7 dozu 5 mg\u2019\u0131 a\u015fmamal\u0131d\u0131r. Ayr\u0131ca, konjestif kalp yetmezli\u011fi, karaci\u011fer hastal\u0131\u011f\u0131 ve maln\u00fctrisyonu olan hastalarda da ba\u015flang\u0131\u00e7 dozu \u22645 mg olmal\u0131d\u0131r.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}